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High levels of circulating autoantibodies (auto-Ab) 
directed  against phosphatidylinositides have been 
identified in  the sera of patients  with malignant tu- 
mors. These polyclonal autoantibodies had higher  av- 
idity  and specificity for phosphatidylinositol (PtdIns) 
than  for  the other phosphatidylinositides. Effects of 
the auto-Ab were studied in smooth muscle myocytes 
in  the PtdIns-involving  transduction mechanism trig- 
gered by activation of al-adrenoceptors.  Noradrena- 
line activated a Ca’+-dependent C1- current through 
the Ca2+-releasing action of inositol 1,4,6-trisphos- 
phate (InsPs) and enhanced the Ca” channel current 
through  a diacylglycerol and  protein  kinase C-depend- 
ent mechanism. External applications of auto-Ab 
(0.03-0.3 mg/ml) were without effect on noradrena- 
line-induced responses whereas  intracellular applica- 
tions (0.0004-0.012  mg/ml) inhibited both C1- current 
activation  and Ca” channel current stimulation. Intra- 
cellular applications of IgG from  healthy  donors  had 
no effect on noradrenaline-induced responses. When 
anti-PtdIns Ab were  preincubated  with  PtdIns  the  in- 
hibition of the noradrenaline-induced responses on 
Ca2+ and C1- channels was not observed. Autoanti- 
PtdIns Ab inhibited also the acetylcholine-activated 
C1- current, confirming that  the acetylcholine response 
was mediated through  the phosphatidylinositol break- 
down. In contrast,  the  autoanti-PtdIns Ab were inef- 
fective  against  the  transduction  pathway after B-adre- 
noceptor activation. Therefore, these results suggest 
that  the biological effect of autoanti-PtdIns Ab results 
from a specific binding  to membrane PtdIns  or  PtdIns 
metabolites and  thereby  prevented InsP, and diacyl- 
glycerol production. These autoanti-PtdIns Ab appear 
to be a new specific tool to  identify  the role of phos- 
phatidylinositides in intracellular tranduction proc- 
esses. 
A variety of cell surface receptors appears to regulate cel- 
lular responses by increasing the concentration of cytoplasmic 
Ca2+  and by activating protein kinase C (1-3). Stimulation of 
these receptors results in  the hydrolysis of a membrane phos- 
pholipid, phosphatidylinositol 4,5-bisphosphate (PtdIns- 
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(4,5)P2)’ by phospholipase C with the consequent generation 
of two second messengers: inositol 1,4,54risphosphate  (InsPJ 
and diacylglycerol  (DAG). InsPs mobilizes intracellular Ca2+ 
whereas DAG activates protein kinase C isoforms to phos- 
phorylate a specific set of proteins (1-5). Activation of al- 
adrenoceptors in portal vein smooth muscle stimulates L-type 
Ca2+ channels (6). This effect is dependent on the activation 
of protein kinase C and may  involve subsequent phosphoryl- 
ation of intracellular proteins. InsPB mediates the release of 
Ca2+ from internal stores, initiating Ca2+-dependent activa- 
tion of C1- channels.  In addition, coupling between w-adre- 
noceptors and phospholipase C is mediated through activation 
of a G-protein insensitive to pertussis toxin (6). 
Circulating autoantibodies (auto-Ab) directed against phos- 
phatidylinositol (PtdIns) have been identified in highly di- 
luted sera (1/15,000) of patients with malignant tumors using 
a reliable immunoenzymatic assay (7, 8). The statistically 
significant immunological response was found in sera of all 
patients with malignancies irrespective of type, grade, or 
organ localization, and histological origin of tissues. High 
levels of the auto-Ab were also found in sera of female 
Sprague-Dawley rats with chemically induced tumors (9). 
Immunochemical analyses of both human and rat auto-Ab 
with adsorption tests and competition experiments in an 
ELISA system have shown a higher avidity and specificity for 
PtdIns than for the other phosphatidylinositides (7-9). In 
view  of the immunochemical properties of the  autoanti-PtdIns 
Ab purified from human  sera we tested  their effects on the 
intracellular  transduction pathway of vascular smooth muscle 
cells involving PtdIns  as a second messenger precursor (6). 
We find that antibodies to phosphatidylinositides block spe- 
cifically the noradrenaline-induced responses, i.e. activation 
of Ca2+-dependent C1- current and enhancement of Ca2+ 
channel  current.  In  contrast,  they  alter  neither the function 
and modulation of  C1- and Ca2+ channels induced by caffeine 
or phorbol esters nor the transduction pathway after  8-adre- 
noceptor activation. These findings confirm that  PtdIns or 
PtdIns metabolites are involved  in the transduction processes 
activated by occupancy of al-adrenoceptors. 
EXPERIMENTAL  PROCEDURES 
Patients-Single serum specimens of patients with malignant tu- 
mors were supplied by the Fondation BergoniB (Bordeaux). Sera of 
The abbreviations used are: PtdIns(4,5)Pz, phosphatidylinositol 
4,5-bisphosphate; Ab, antibody(ies); PtdIns, phosphatidylinositol; 
PtdIns(l)P, phosphatidylinositol 4-monophosphate; Inspa, myo-ino- 
sitol 1,4,5-trisphosphate; OAG, I-oleoyl-2-acetylglycerol; PtdSer, 
phosphatidylserine; DAG,  diacylglycerol; PDBu, phorbol 12,13-dibu- 
tyrate, ELISA, enzyme-linked immunosorbent assay; HEPES,  442- 
hydroxyethy1)-1-piperazineethanesulfonic acid; EGTA, [ethylene- 
bis(oxyethylenenitrilo)]tetraacetic acid. 
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patients with  malignant  leukemia  were  supplied by the Centre Fran- 
Gois Magendie, Haut-LBv6que Hospital (Bordeaux). Control blood 
samples of healthy  donors were  given  by the Centre de Transfusion 
Sanguine  (Bordeaux). 
Purification of Human  Sera-One ml  of  each  serum  was precipi- 
tated with a 50% (NH4),S04 solution followed by dialysis against a 
lo-' M phosphate  buffer  containing 4 g/liter NaCl,  pH  7.4,  for 72 h 
at 4 "C. The sera were then Sephadex G-200 chromatographed 
through a column (50 X 1 cm, Pharmacia  LKB  Biotechnology  Inc.) 
and eluted  with the same  buffer.  Each fraction was subjected to an 
ELISA  for  evaluating its  anti-PtdIns activity. Ab avidity and speci- 
ficity were  assayed  by competition  experiments  as  described  below. 
Zmmunoenzymatic  Test for Detection and Characterization of Auto- 
antibodies  in  Human  Sera-The anti-phosphatidylinositide activity 
in sera of patients with  malignant tumors (leukemia, breast cancer, 
gastrointestinal cancer) and of healthy  donors was  assayed with  an 
ELISA (7,8). Human  auto-Ab  avidity and specificity  were  evaluated 
by competition  experiments.  They were  performed as follows.  Each 
compound (PtdIns containing either stearic and arachidonic  acids or 
linoleic and palmitic acids, phosphatidylinositol 4-monophosphate 
(PtdIns(4)P), PtdIns(4,5)Pz, myo-inositol, InsPs, 1-oleoyl-2-acetyl- 
glycerol (OAG) and phosphatidylserine (PtdSer), all  from Sigma) was 
preincubated, at various concentrations (from lo-' to lo-" M), with 
human sera diluted 15,000-fold or purified IgG fractions diluted 
15,000-fold  (7.10-'  mg/ml) in a lo-' M phosphate  buffer containing 
0.15 M NaCl and 10% glycerol.  After 18 h at 4 "C,  each  mixture  was 
applied onto well plates coated with PtdIns or thyroglobulin. The 
absorbances  in well plates were  measured at 492  nm with a Multiskan 
spectrophotometer.  Experimental  values were corrected by subtract- 
ing  blank  values  read  on well plates coated  with  thyroglubulin. The 
specific  binding  was  revealed  with anti-human IgG  Ab (diluted 
20,000-fold)  labeled  with  peroxidase and orthophenylenediamine, as 
described  previously (7,8). 
Adsorption of Purified  Fractions-To  determine anti-PtdIns activ- 
ity, purified  IgG fractions were preincubated or not with a M 
PtdIns solution  for 16 h at 4 "C. Then both fractions were  assayed  in 
an ELISA  for their anti-PtdIns activity. The binding was  revealed as 
indicated above. 
Electrophysiological Recordings-Single rat portal vein myocytes 
were  isolated  by  enzymatic dispersion  similar to that described  pre- 
viously  (10) and maintained  in short term primary  culture  for 40  h. 
Whole  cell  membrane currents were  measured at 30 2 1 "C  using the 
standard patch-clamp  technique (11). For the recordings  of C1- cur- 
rent, the extracellular medium (reference solution) contained (in 
mM):  NaCl,  130;  KCl, 5.6; CaC12,  2.5;  MgCl,, 1; glucose, 11; HEPES, 
8, pH  7.4,  with  NaOH. The basic pipette solution  contained (in mM): 
CsCl, 130; HEPES, 10,  pH  7.3,  with  CsOH.  CsCl was used instead of 
KC1  in the pipette solution to block outward  potassium currents. For 
the recordings of Caz+ channel current, 5 mM BaCl?  was substituted 
for CaC1, in the reference  solution, and 5 mM EGTA,  2.5 mM Na2ATP, 
1 mM MgCl,  were  added to the basic pipette solution. 
For the studies of Ca2+-activated C1- current, noradrenaline 
(Sigma) and caffeine (Merck) were applied with a pressure ejector 
from a glass pipette close to  the cell. The effects of noradrenaline, 
isoprenaline, and phorbol  12,13-dibutyrate  (Sigma) on Ca2+ channel 
currents were  recorded during bath perfusion of these agents. Phen- 
tolamine,  prazosin, and propranolol  (Sigma) were  used as a- and 8- 
adrenoceptor  blocking  agents. 
Currents were filtered at 1 kHz (-343 frequency), stored, and 
analyzed using an IBM PC computer (P-clamp system, Axon) as 
described  previously (12). Capacitive and leakage currents were  digi- 
tally subtracted. The values  given are the means f S.E.,  with n the 
sample size.  Significance  was tested by  means  of Student's t test. 
RESULTS 
Avidity and Specificity of Auto-Ab from  Human  Sera  Puri- 
fications-The anti-PtdIns activity was expressed with the 
following ratio: R = optical  density  (OD) of cancer  patients' 
sera  or IgG fractions -OD of controls sera or control IgG 
fractions/OD of controls  sera  or  control IgG fractions. For 
sera used in  these  experiments  ratios were found  between 1.2 
and 3.25. After Sephadex G-200 chromatography, the anti- 
PtdIns  activity  was always found  in  the IgG elution  peaks, as 
noticed previously (9). The  ratio  values of the selected  frac- 
tions were increased to 2.05 and 4.05 in comparison with 
control  purified IgG, indicating a high level of anti-PtdIns  in 
sera of breast cancer patients ( n  = 50). Fig. 1 shows the 
avidity  and specificity of one of these IgG fractions of breast 
cancer  serum, given by displacement  curves  established from 
competition  experiments. The  best  avidity  determined a t  half- 
maximal  absorbance (BIBo = 0.5) was found  for  PtdIns.  The 
avidity for PtdIns was identical when the fatty acids were 
either  stearic  and  arachidonic  acids  or linoleic and  palmitic 
acids ( n  = 4). In contrast,  the  autoanti-Ab recognized about 
15-fold less  both  PtdIns(4,5)Pz  and  PtdIns(4)P  and 100-fold 
less  myo-inositol and InsP3.  Nonsignificant  displacement was 
observed with OAG, a synthetic analog of DAG and with 
PtdSer.  Other  membrane  phospholipids  and lipids tested  such 
as phosphatidylcholine, phosphatidylethanolamine, ganglio- 
sides, sphingosine, sphingomyelin, and cardiolipin were not 
recognized at all. All IgG fractions  purified  from 150 various 
cancer  sera  (breast,  gastrointestinal  tract,  leukemia) showed 
the same Ab avidity and specificity whereas no effect was 
observed with purified control IgG (30 sera). Although the 
recognition of auto-Ab  sites  is  mainly  related  to  the  presence 
of PtdIns molecules it  is likely that  several  antibodies  that 
specifically recognized PtdIns,  PtdIns(4)P,  or  PtdIns(4,5)Pz 
are  present  in  the IgG fraction of cancer sera. 
Effects of Autoanti-Ptdlns Antibodies on Noradrenaline 
Stimulation of Ca2+ and Cl- Channels-Autoanti-PtdIns Ab 
from  breast  cancer  sera were used to prove directly  the  in- 
volvement of PtdIns  breakdown  in  the  noradrenaline effects 
in vascular smooth muscle cells. Incubation of the cells in 
external  reference  solution  containing  autoanti-PtdIns Ab a t  
concentrations  ranging  between 0.03 and 0.3 mg of IgG/ml 
for 2 or 24 h had  no effect on  either  the  maximal Ca2+ channel 
current  elicited  by a membrane  depolarization  to 0 mV from 
a holding  potential of -60 mV or  the C1- current elicited by 
ejection of M noradrenaline ( n  = 8). In the presence of 
external autoanti-PtdIns Ab the Ca2+ channel current was 
increased by 55.5 f 6.1% ( n  = 5) after the addition of M 
NA. This stimulatory effect was not significantly different 
from  that  obtained  in  the  absence of autoanti-PtdIns Ab (65.1 
& 6.5%, n = 6 ,p  > 0.05). It has  to  be  noted  that  the  stimulatory 
effects of noradrenaline were blocked in M phentolamine 
and M prazosin  whereas,  they  remained  unchanged  in 
M propranolol,  indicating  that  the  responses  to  noradren- 
aline were mediated  by  al-adrenoceptors. 
In contrast, alterations of the noradrenaline-induced re- 
sponses were observed when the autoanti-PtdIns Ab were 
-12 -11 -10 -9 -8 -7 -6 -5 
log c 
FIG. 1. Displacement curves  estshlished by competition ex- 
periments in an ELISA system between PtdIns coated on well 
plates and each of the followinn Zompounds: PtdIns (O), 
PtdIns(4)P (A), PtdIns(4,5)Pz (V), Ins(1,4,6)Ps (O), Ins (W), 
PtdSer (X), and OAG (A) previously incubated, at various 
concentrations, with an IgG fraction (7.10-' mg/ml) purified 
from human breast cancer sera. Absorbance  values are expressed 
as BIBo with BO = OD without competitors and B = OD with 
competitors. C = competitor molar concentration. Data points are 
the means of three determinations. Standard deviations are smaller 
than the symbol  size. 
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intracellularly applied. Fig. 2A shows a typical C1- current 
induced by noradrenaline ejection M) in a cell main- 
tained at a holding potential of  -60 mV, under control  con- 
ditions. Noradrenaline was effective in 80% of the tested cells 
(n = 20), and the mean amplitude of the noradrenaline- 
induced C1- current was -279.3 f 50.1 pA ( n  = 16). When 
the purified IgG  (0.012 mg/ml) from breast cancer sera was 
added to  the basic pipette solution, the noradrenaline-induced 
C1- current was completely abolished in 80% of the tested 
cells (n = 20; Fig. 2B) whereas in the remaining cells nor- 
adrenaline was still able to activate a C1- current, but  the 
mean current amplitude measured at a holding potential of 
-60 mV was strongly reduced to -50.8 f 30.6 pA ( n  = 4, 
p < 0.01). In addition, when the cells were injected with 
control purified IgG from healthy  patients at a  concentration 
identical to  that used for the  autoanti-PtdIns Ab, no signifi- 
cant modifications of the mean amplitude of the noradrena- 
line-induced C1- current (Fig. 2C) were observed in compari- 
son  to control cells ( p  > 0.05, n = 6). Finally, the intracellular 
application of the purified IgG fractions (0.012 mg/ml) from 
breast cancer sera preincubated with a lo-' M solution of 
PtdIns was also without effect (Fig. 2 0 ) .  Six of the seven 
tested cells displayed a C1- current  in response to noradren- 
aline ejection, and the mean amplitude of the C1- current 
measured at a holding potential of -60 mV was not signifi- 
cantly modified ( p  > 0.05, n = 6). These  results suggest that 
the inhibition of the noradrenaline-induced C1- current is 
caused by the  anti-PtdIns activity of the IgG fraction of breast 
cancer sera. 
We also tested the effects of the  autoanti-PtdIns Ab on the 
noradrenaline-induced enhancement of the Ca2+  channel  cur- 
rent. Under control conditions, the application of noradren- 
aline (lo-' M) produced an increase in  the amplitude of the 
Ca2+  channel  current evoked  by depolarization to 0 mV from 
a holding potential of -60 mV (Fig. 3A). This increase was 
observed in 80% of the cells ( n  = lo), and  the mean percentage 
of current increase was 65.9 k 7.9% ( n  = 8). Intracellular 
application of the purified IgG from breast cancer sera dose 
dependently reduced the stimulation induced by M nor- 
adrenaline. The effects of various concentrations of IgG from 
the same batch are  illustrated  in Fig. 3. In the presence of 
0.0004 mg  of IgG/ml  (Fig. 323) and 0.0012 mg  of IgG/ml (Fig. 
3C) in the pipette solution, the noradrenaline-induced en- 
hancement of the Ca2+ channel  current was reduced to 40.7 
f 2.4% ( n  = 3) and 26.7 f 8.2% (n = 4), respectively. Complete 
A B 
NA 
FIG. 2. Effect of noradrenaline (NA)  on C1- current re- 
corded with  the whole cell patch-clamp technique in single 
vascular smooth  muscle cells isolated from rat  portal vein. 
Ca2+-activated C1- current was recorded at a holding potential of -60 
mV in response to the application of noradrenaline M) for 200 
ms in control ( A ) ,  in the presence of 0.012 mg/ml IgG from breast 
cancer serum ( B ) ,  and from healthy patients (C). in the pipette 
preincubated with a lo-' M solution of PtdIns (D) was added to  the 
solution, and when 0.012 mg/ml IgG from breast cancer serum 
pipette solution. 
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FIG. 3. Effect of noradrenaline (lo-' M) on Ca2+ channel 
current. Ca2+ channel  current was  evoked by a depolarization to 0 
mV from a holding potential of -60 mV before (a )  and during the 
application of noradrenaline ( b )  in control conditions ( A )  or  in the 
presence of purified IgG  from breast cancer serum at 0.0004 mg/ml 
( B ) ,  0.0012 mg/ml (C), and 0.012 mg/ml (D) in the pipette solution. 
The noradrenaline-induced increase in Ca2+ channel  current was  dose 
dependently inhibited by autoanti-PtdIns Ab. In contrast, when 0.012 
mg/ml purified IgG from healthy patients ( E )  or when 0.012 mg/ml 
IgG from breast cancer serum incubated with a lo-' M solution of 
PtdIns (F) was added to  the pipette solution, the increase in the Ca2+ 
channel current induced by noradrenaline was similar to  that ob- 
tained under control conditions. Experimental data were obtained 
from different cells. 
inhibition of the noradrenaline effect on the Ca2+ channels 
was obtained by increasing the concentration of autoanti- 
PtdIns Ab to 0.012  mg  of IgG/ml (n = 7; Fig. 30).  Intracellular 
applications of either purified IgG from healthy patients 
(0.012 mg/ml; Fig. 3E) or purified IgG from breast cancer 
sera preincubated with a lo-' M solution of PtdIns (0.012  mg/ 
ml;  Fig. 3F) had no effects on the increase of the Ca2+ channel 
current induced by M noradrenaline ( p  > 0.05, n = 7). 
Therefore, the inhibition of the noradrenaline-induced en- 
hancement of Ca2+ channel current by IgG fractions from 
breast cancer sera seems to be linked directly to  the autoanti- 
PtdIns Ab found in these sera. Similar inhibitory effects of 
the noradrenaline-induced responses were also obtained with 
IgG from leukemia and  gastrointestinal cancer sera ( n  = 10). 
A possible direct effect of the  autoanti-PtdIns Ab on C1- 
channels, Ca2+ channels, or intracellular Ca2+ stores was 
checked by using both caffeine and phorbol-12,13-dibutyrate 
(PDBu). Caffeine is known to release Ca2+ from intracellular 
stores whereas phorbol esters can directly activate protein 
kinase C. Fig. 4 shows the relative amplitude of the Ca2+ 
channel  current evoked by repetitive depolarizations to 0 mV 
from a holding potential of -60 mV as  a function of time. 
Under control conditions, 10"j M PDBu produced an increase 
in the Ca2+ channel  current amplitude of 65.9 f 3.4% ( n  = 
11;  Fig. 44). In  the presence of autoanti-PtdIns Ab  (0.012  mg 
of IgG/ml) in  the pipette solution, noradrenaline ( W 5  M) had 
no effect on the Ca2+  channel  current amplitude (Fig. 4B). 
After 7 min of continuous recording, the current amplitude 
was similar to  that obtained at  the beginning of the experi- 
ment, suggesting that  autoanti-PtdIns Ab did not accelerate 
the run-down phenomenon which  was  weak at  the stimulation 
frequency used (0.05 Hz; 12). A subsequent application of 
PDBu induced an increase in  the Ca2+ channel  current (66.5 
f 11.0%, n = 6, p > 0.05) similar to  that obtained in control 
conditions (Fig. 4B).  These results indicate that  the protein 
kinase C remains functional and  that Ca2+ channels  still have 
the property to be stimulated through protein kinase C acti- 
vation. Similarly, in the presence of the  autoanti-PtdIns Ab, 
caffeine was still able to induce a  Ca2+-activated C1- current 
whereas prior application of noradrenaline was ineffective 
(Fig. 5A). This observation reveals that the internal Ca2+ 
stores  are  not empty and  that C1- channels can be opened by 
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FIG. 4. Effects of PDBu on Ca2+ channel current. A, time 
course of the peak Caz+ channel current during the application of 
M PDBu. Inset, current  traces corresponding to small letters on 
the curve. B, time course of the peak Ca2+ channel current during 
successive applications of noradrenaline (lo-' M) and PDBu M) 
in cells dialyzed with a pipette solution containing 0.012 mg/ml 
autoanti-PMIns Ab. PDBu induced a  sustained increase in the Ca2+ 
channel  current whereas noradrenaline was ineffective. Inset, current 
traces corresponding to small letters on the curve. Currents are 
expressed as a fraction of their control values ( Z / Z c ) .  
A caceine 10-'M 
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FIG. 5. Effects of caffeine and acetylcholine on Ca2+-acti- 
vated C1- current elicited from a holding potential of -60 mV. 
A, under control conditions, the application of caffeine (lo-' M) 
evoked a large transient inward current ( a ) .  In the presence of 
autoanti-PtdIns Ab (0.012 mg/ml) in  the pipette solution, caffeine 
(lo-' M) still elicited a large C1- current whereas noradrenaline ( N A )  
( M) was ineffective ( b ) .  B, under control conditions, acetylcholine 
(ACh) ( W 5  M) induced activation of a C1- current ( a )  which was 
completely inhibited in the presence of autoanti-PtdIns Ab (0.012 
mg/ml) in the pipette solution ( b ) .  The external solution contained 
2.5 mM Ca2+,and  there was no EGTA in the pipette solution. 
a rise in the cytosolic Ca2+ concentration. In addition, the 
presence of the  autoanti-PtdIns Ab in the pipette does not 
alter the function and modulation of both C1- and Ca2+ 
channels by substances other  than noradrenaline. 
To determine whether the  autoanti-PtdIns Ab may interact 
with the same transduction process activated by muscarinic 
receptor activation but  not with other membrane transduction 
processes, we tested their effects on acetylcholine and iso- 
prenaline-induced responses. In smooth muscle, acetylcholine 
has been shown to produce a G-protein-mediated stimulation 
of phospholipase C activity (13). As illustrated in Fig.  5B, the 
acetylcholine activated C1- current was completely abolished 
when autoanti-PtdIns Ab (0.012 mg  of IgG/ml) were applied 
intracellularly ( n  = 4). On the other hand, it has been de- 
scribed recently that P-adrenergic receptor activation stimu- 
lates the L-type Ca2+ channel  current of smooth muscle cells 
(14,15)  and  that a similar effect can be produced by forskolin 
which directly activates adenylate cyclase (14). Although the 
transduction coupling between P-adrenoceptors and Ca2+ 
channels is not completely understood in smooth muscle, it 
does not involve activation of phospholipase C. When M 
isoprenaline was applied in the presence of M phentola- 
mine, the maximal Ca2+ channel current was increased by 
47.4 f 12.6% ( n  = 5; Fig. 6A). The increase in Ca2+  channel 
current induced by isoprenaline was suppressed after a 10- 
min pretreatment with M propranolol, indicating that 
this effect was mediated through 8-adrenoceptors. Intracel- 
lular applications of autoanti-PtdIns Ab (0.012 mg of IgG/ 
ml) had no effect on the isoprenaline-induced stimulation of 
Ca2+ channel current, as illustrated in Fig. 6B, ( p  > 0.05, 
n = 3). 
DISCUSSION 
The in vivo administration of poly and monoclonal Ab 
directed against endogenous compounds has been described 
previously (16-20). A monoclonal Ab against PtdIns(4,5)P2, 
produced from mice, has been injected into NIH 3T3 cells 
transformed by transfection with cloned human activated c- 
Ki-rus and  v-Ha-rus genes. These  authors have thus shown 
that transformation by these types of oncogenes switches over 
the mitogenic signaling pathway to  a pathway dependent on 
PtdIns(4,5)P2 (21). More recently, microinjections of the 
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FIG. 6. Effects of isoprenaline on Ca2+ channel current. A,  
time course of the peak Ca2+ channel  current during application of 
isoprenaline (10"j M). Inset, current traces corresponding to small 
letters on the curve. B, time course of the peak Ca2+ channel  current 
during application of isoprenaline (1O"j M) in cells dialyzed with a 
pipette solution containing 0.012  mg/ml autoanti-PtdIns Ab. Inset, 
current  traces corresponding to small letters on the curve. Currents 
are expressed as a fraction of control values (I/Zc). 
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monoclonal Ab directed against PtdIns(4,5)P2  into  neonatal 
rat vascular smooth muscle cells had been used to show that 
the rise in intracellular Ca2+ concentration induced by plate- 
let-derived growth factor involved PtdIns(4,5)Pz  or 
PtdIns(4,5)P2 metabolism (22). However, little  has been re- 
ported with auto-Ab of human  sera from patients with dis- 
eases. Obstacles encountered for the use of auto-Ab from 
human  sera are: (i)  the antigen recognition is not  or poorly 
defined; (ii) the Ab levels are often low; and (iii) the Ab 
avidity and specificity are  rather poor and often not known. 
Evaluation and characterization of autoanti-PtdIns Ab in  sera 
of cancer patients have shown that  the level of these auto-Ab 
is high as the  autoanti-PtdIns activity can be identified in 
highly diluted sera (1/15,000) and that both avidity and 
specificity have been found to be higher for PtdIns  than for 
the other phosphatidylinositides (7-9;  Fig. 1). 
For the  first time, we report  in the present  study the in vivo 
use of human autoanti-PtdIns Ab. The auto-Ab inhibited 
both  the noradrenaline-induced enhancement of  Ca" channel 
current and the noradrenaline- and acetylcholine-activated 
Ca2+-dependent C1- current in portal vein smooth muscle 
cells. In  contrast, the effects of phorbol 12,13-dibutyrate and 
caffeine were unchanged in  the presence of auto-Ab. These 
results indicate that Ca2+ channels, C1- channels, protein 
kinase C, and intracellular Ca2+ stores are  not directly affected 
by the  autoanti-PtdIns Ab which should act on a  step of the 
transduction process between al-adrenoceptors  and phospho- 
lipase C. As the avidity of the  autoanti-PtdIns Ab for InsPs 
and OAG is rather low, it is unlikely that  the inhibition of 
the noradrenaline-induced responses may be attributed to 
direct binding of the auto-Ab to either  InsP3  and DAG inside 
the cell. In addition, when polyclonal IgG from healthy  pa- 
tients or IgG fractions from patients with malignant tumors 
incubated with PtdIns were added to  the pipette solution, the 
noradrenaline-induced responses were not altered. 
Inhibition of both noradrenaline and acetylcholine effects 
was only seen when the purified IgG from cancer sera was 
intracellularly applied, suggesting that  it could result from 
the binding of the  autoanti-PtdIns Ab to PtdIns or to 
PtdIns(4)P  and PtdIns(4,5)Pz, which are bound to  the inner 
side of the plasma membrane. Although the auto-Ab avidity 
for PtdIns is about 15-fold higher than for PtdIns(4)P  and 
PtdIns(4,5)P2  and  the  PtdIns concentration  in smooth muscle 
is  estimated to be 10-fold higher than those of PtdIns(4)P 
and  PtdIns(4,5)P2 (23), interaction of the  autoanti-PtdIns Ab 
with these two phosphorylated forms of PtdIns  cannot be 
excluded.  Moreover, the IgG concentrations used for electro- 
physiological experiments are 10-100-fold higher than those 
used for immunological studies. However, it is likely that  the 
IgG concentration reached in the cytoplasm may be lower 
than  that of the pipette solution as diffusion of large  molecules 
such  as IgG may  be limited. As the inhibitory action of the 
autoanti-PtdIns Ab inside the cell is similarly observed on 
the two electrophysiological responses induced by noradren- 
aline, i.e. activation of Ca'+-dependent C1- current  and  en- 
hancement of Ca2+ channel  current,  these  results suggest that 
both  InsP3  and DAG production are prevented by the auto- 
Ab. In  contrast,  other  transduction pathways such that me- 
diated through P-adrenoceptor activation are  not affected at 
all by intracellular dialysis of the autoanti-PtdIns Ab. As 
coupling between the P-adrenoceptor and  the Ca2+ channel  in 
smooth muscle  may  involve either  a direct coupling by a G.- 
type  protein (15) or  intracellular cyclic AMP (14) these results 
demonstrate the specificity of the  autoanti-PtdIns Ab against 
the membrane transduction pathway involving phosphatidyl- 
inositol breakdown. 
Use of human  autoanti-PtdIns Ab provides further evidence 
for the involvement of phospholipase C  and phosphatidyli- 
nositides in the intracellular transduction mechanism trig- 
gered by al-adrenoceptor activation in vascular smooth mus- 
cle  cells. In several publications, neomycin, which is believed 
to prevent enzymatic action of phospholipase C by binding to 
PtdIns(4,5)P2,  has been used to demonstrate the involvement 
of phospholipase C  in coupling mechanisms between receptors 
and effectors (24-26).  However, the effects of neomycin are 
not very specific as neomycin  may produce an inhibition of 
Ca2+ influx (27) and changes in receptor-agonist binding 
affinity (28). Therefore, autoanti-PtdIns Ab appear to be a 
more specific tool to demonstrate the role of PtdIns  in  intra- 
cellular transduction processes. Although circulating au- 
toanti-PtdIns Ab from cancer patient  sera do not bind to both 
PtdIns and phosphoinositides in normal vascular smooth 
muscle cells when applied extracellularly, this observation 
does not exclude the possibility that auto-Ab may interact 
with PtdIns  in transformed  and injured cells. 
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